KC
IKT icon

Kepos Capital’s Inhibikase Therapeutics IKT Stock Holding History

Kepos Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-116,667
Closed -$1.04M – 536
2022
Q1 		$1.04M Hold
116,667
– – 0.08% 175
2021
Q4 		$1.03M Hold
116,667
– – 0.09% 200
2021
Q3 		$1.33M Hold
116,667
– – 0.09% 274
2021
Q2 		$1.96M Buy
+116,667
New +$3.43M 0.15% 231

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Kepos Capital's IKT Position: Q2 2022 in Review

Kepos Capital sold out of Inhibikase Therapeutics (IKT) in Q2 2022, closing a stake of 116,667 shares — an estimated $1.04M sold.

Kepos Capital first reported a position in IKT in Q2 2021 and held it in 4 quarters. The position peaked at $1.96M in Q2 2021. 22 funds tracked by Wall St. Rank hold IKT as of Q2 2022.

  • Kepos Capital reported no remaining Inhibikase Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kepos Capital sold 116,667 Inhibikase Therapeutics shares in Q2 2022, an estimated $1.04M.
  • Kepos Capital first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 4 quarters.
  • Kepos Capital's Inhibikase Therapeutics position peaked at $1.96M in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2022.

Based on Kepos Capital's 13F filing for Q2 2022, filed 12 Aug 2022.